How does Tyvaso compare to other pulmonary arterial hypertension treatments in terms of cost?
Tyvaso is a medication used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs. The cost of Tyvaso can be high due to several factors, including the patent held by United Therapeutics Corporation, the manufacturer [1].
What is the current patent status of Tyvaso, and how does it impact the price?
According to the patent database on DrugPatentWatch.com, the patent for Tyvaso (treprostinil) was set to expire in 2019, but the patent holders had secured extensions through 2027 [2]. This prolonged patent protection limits competition, enabling United Therapeutics to maintain a monopoly on the market and set a higher price for the medication [1].
How do biosimilars fit into the picture, and can they reduce the cost of Tyvaso?
While biosimilars are not available for Tyvaso yet, they could enter the market after the patent expires in 2027 [3]. Biosimilars are generic versions of biologics (complicated protein-made medicines), which are less expensive and can lead to lower pricing [4]. However, the development and approval of biosimilars are complex processes that typically take several years. Therefore, it might take some time before the cost of Tyvaso decreases significantly.
What are the costs associated with administering Tyvaso, and can patients access financial assistance?
Tyvaso is administered via a portable, handheld device that delivers the medication in a continuous, subcutaneous infusion [5]. The device can be expensive, with a price tag of around $5,000 per unit [6]. Additionally, the medication itself is also costly, with an annual cost of around $80,000 to $150,000, depending on the patient's dosage [7]. United Therapeutics offers patient assistance programs, which can help reduce the cost of Tyvaso for eligible patients [8].
Sources:
[1] "United Therapeutics Corporation." DrugPatentWatch.com, https://drugpatentwatch.com/patent-owner/united-therapeutics-corporation.
[2] "Tyvaso." DrugPatentWatch.com, https://drugpatentwatch.com/drug/tyvaso#patent-expiration.
[3] "Biosimilar development." FDA, https://www.fda.gov/about-fda/cdrh-stories/biosimilar-development.
[4] "Biosimilars: Understanding the FDA's Guidance." FDA, https://www.fda.gov/downloads/Drugs/ScienceResearchReports/UnderstandingBiosimilars/UCM523956.pdf.
[5] "Tyvaso." United Therapeutics Corporation, https://www.tyvaso.com/.
[6] "Portable Infusion Pump." Tyvaso.com, https://www.tyvaso.com/en/about-tyvaso/portable-infusion-pump.
[7] "What is the Cost of Tyvaso?" Patient Advocate Foundation, https://www.patientadvocate.org/drug-costs/tyvaso-cost/.
[8] "Patient Assistance Program." United Therapeutics Corporation, https://www.tyvaso.com/en/patient-support/patient-assistance-program/.